LiveNova Logo

TandemLife is now a part of LivaNova, Learn More Here.

COVID-19 UPDATES:The U.S. Food and Drug Administration (FDA) issued guidance on April 6, 2020 to temporarily expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19) public health emergency. As a result of the guidance, cardiopulmonary devices, including select devices from TandemLife | LivaNova, are now temporarily indicated for ECMO therapy greater than 6 hours. To read the full announcement, click here.



855 336 3051 REIMBURSEMENT

800 373 1607 US

412 507 6182 INTERNATIONAL

ECLS Products among the Most Exciting Cardiac Care Developments

Posted on February 28, 2017 | Uncategorized

In a recent interview  Zain Khalpey, M.D (Director, Artificial Heart & ECMO Program, Banner University), describes the method of treating emergent cardiac failure situations with ECLS prior to full Left Ventricular unloading as the paradigm shift need to help improve results.

Click the following link for the full interview:


_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

We recently participated in Mediaplanet’s Heart Healthy campaign where we united with likeminded industry leaders to educate the public about preventative measures they can take to avoid falling victim to cardiovascular disease, while also highlighting industry breakthroughs and innovations that provide hope to those already affected. The campaign was distributed through USA TODAY on February 24th 2017 and is published online. For the full campaign, visit: